Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-27

Study Completion Date

2023-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial using Qbrexza Cloths to treat hyperhidrosis of amputation sites. There is a 2 week screening period where patients will use an activity monitor to establish baseline activity level, then patients will be randomized to receive either Qbrexza cloths or placebo for 4 weeks, then a 2 week washout, and then a 4-week cross-over treatment period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2

NCT03416348

Hyperhidrosis

COMPLETED PHASE1

Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users

NCT05501444

Hyperhidrosis Residual Limbs

COMPLETED NA

Optimizing Prosthetic Prescription to Mitigate the Effects of Perspiration

NCT07024342

Amputation Prosthesis User

ACTIVE_NOT_RECRUITING NA

Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy

NCT03174366

Charcot Joint of Foot

COMPLETED PHASE3

Adherence and Perspiration While Wearing Lower Limb Prostheses

NCT03900845

Lower Extremity Amputation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Approximately 1 in 190 people in the United States have experienced a limb amputation. Of these patients with amputations, over sixty percent suffer from hyperhidrosis at the amputation site. Amputation site hyperhidrosis interferes with these patients' daily activities as well as their ability to engage in vigorous activity beneficial to their overall health. In fact, amputees identified heat and sweating as what reduces their quality of life more than any other problem, even pain. Despite the significant impact hyperhidrosis has on amputees' quality of life and ability to stay physically active, there are no self-administered, non-invasive, well-tolerated treatments for amputation site hyperhidrosis. Botulinum toxin injections are an available treatment option for focal hyperhidrosis. However, the large surface area covered by the prosthetic and prosthetic sleeve often necessitates very large volumes of botulinum toxin for effective treatment at amputation sites. This is costly, making it difficult to be able to treat the entire affected area. Botulinum toxin also requires office visits and repeat treatments every 4-6 months.

Glycopyrronium cloths are a unique treatment possibility, because they can easily be used over a large body surface area and can easily be self-administered at home. At this time, glycopyrronium cloths are only FDA approved for use in the axillae. There are two primary differences between the use of these cloths at amputation sites and axillae: 1) the amputation site is occluded during daytime hours by the prosthetic and 2) the area treated for amputation-site hyperhidrosis (the entire area covered by the prosthetic sleeve) is typically a much larger surface area than the axillae. These factors could significantly increase systemic absorption of glycopyrronium and cause systemic side effects. In order to minimize these effects, the medication will be applied at night, when the site is not occluded. Frequent visits with the investigator will also encourage early reporting of symptoms which could be the result of systemic side effects associated with use on a larger surface area. Patient reported outcomes will be used to determine effectiveness.

This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial.

Participants will be randomized, using a 1:1 ratio, to one of 2 arms:

* Arm #1: At Baseline participants will receive active treatment for 4 weeks, completing a 1 week wash out period and then concluding with 4 weeks of placebo treatment
* Arm #2: At baseline participants will receive placebo for 4 weeks, completing a 1 week washout period and then concluding with active treatment for 4 weeks.

Primary Objective 1. Determine if daily use of glycopyrronium cloths applied to the amputation site decreases hyperhidrosis severity and improved fit and function of the prosthetic as measured by patient reported outcome measures.

Primary Endpoints

1\. Determine the change in ASDD-m Impact scores between the end of the treatment and placebo periods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amputation Hyperhidrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Participants and investigators in the trial will be blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glycopyrronium Cloths then Placebo

Participants that are randomized to Glycopyrronium cloths for 4 weeks, then 2 week wash out, then cross over to placebo cloths for 4 weeks.

Group Type OTHER

glycopyrronium cloths

Intervention Type DRUG

Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Placebo

Intervention Type DRUG

Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.

Placebo then Glycopyrronium Cloths

Participants that are randomized to placebo cloths for 4 weeks, then 2 week wash out, then cross over to Glycopyrronium cloths for 4 weeks.

Group Type OTHER

glycopyrronium cloths

Intervention Type DRUG

Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Placebo

Intervention Type DRUG

Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glycopyrronium cloths

Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Intervention Type DRUG

Placebo

Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Qbrexza Cloths

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. History of limb amputation with limb-amputation surgery at least 6 months ago
2. Have a prosthetic device

4\. HDSS of 3 or greater (at screening) 5. ASDD-m Item 2 severity score \>= 4 (at screening) 6. PFFQ score \>= 4 (at screening)

Exclusion Criteria

1. Open sores or wounds on residual limb (at screening and baseline)
2. Known sensitivity to glycopyrronium tosylate or other component of Qbrexza
3. Pregnant or lactating.
4. Use of botulinum toxin within 1 year of the baseline visit
5. Use of topical aluminum chloride within 1 month of the baseline visit
6. Any significant concurrent condition that could adversely affect the patient's participation and/or the assessment of the safety and efficacy in the study in the opinion of the investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No